Biofrontera Inc., BFRI, is a biopharmaceutical company that develops and provides dermatological products for the treatment of skin diseases in the US.
It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy.
BFRI is currently one of the most shorted stocks with some sources stating 84.91% of the free float as short.
The price is up more than 400% and the majority of short positions are under water.
It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy.
BFRI is currently one of the most shorted stocks with some sources stating 84.91% of the free float as short.
The price is up more than 400% and the majority of short positions are under water.